135 related articles for article (PubMed ID: 7738219)
1. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Shader RI
J Clin Pharmacol; 1994 Dec; 34(12):1222-7. PubMed ID: 7738219
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Wright CE; Shader RI
J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
[TBL] [Abstract][Full Text] [Related]
3. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
[TBL] [Abstract][Full Text] [Related]
4. Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.
Jurima-Romet M; Wright M; Neigh S
Br J Clin Pharmacol; 1998 Mar; 45(3):318-21. PubMed ID: 10896409
[TBL] [Abstract][Full Text] [Related]
5. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
Rodrigues AD; Mulford DJ; Lee RD; Surber BW; Kukulka MJ; Ferrero JL; Thomas SB; Shet MS; Estabrook RW
Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
[TBL] [Abstract][Full Text] [Related]
6. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
Jurima-Romet M; Crawford K; Cyr T; Inaba T
Drug Metab Dispos; 1994; 22(6):849-57. PubMed ID: 7895601
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes.
Hey JA; del Prado M; Kreutner W; Egan RW
Arzneimittelforschung; 1996 Feb; 46(2):159-63. PubMed ID: 8720305
[TBL] [Abstract][Full Text] [Related]
8. Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.
Moody DE; Walsh SL; Rollins DE; Neff JA; Huang W
Clin Pharmacol Ther; 2004 Aug; 76(2):154-66. PubMed ID: 15289792
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
Raeissi SD; Guo Z; Dobson GL; Artursson P; Hidalgo IJ
Pharm Res; 1997 Aug; 14(8):1019-25. PubMed ID: 9279883
[TBL] [Abstract][Full Text] [Related]
10. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method.
Shibata Y; Takahashi H; Chiba M; Ishii Y
Drug Metab Pharmacokinet; 2008; 23(5):328-39. PubMed ID: 18974610
[TBL] [Abstract][Full Text] [Related]
12. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
Honig PK; Wortham DC; Zamani K; Conner DP; Mullin JC; Cantilena LR
JAMA; 1993 Mar 24-31; 269(12):1513-8. PubMed ID: 8445813
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes.
Ling KH; Leeson GA; Burmaster SD; Hook RH; Reith MK; Cheng LK
Drug Metab Dispos; 1995 Jun; 23(6):631-6. PubMed ID: 7587944
[TBL] [Abstract][Full Text] [Related]
14. Ketoconazole potentiates terfenadine-induced apoptosis in human Hep G2 cells through inhibition of cytochrome p450 3A4 activity.
Wang YJ; Yu CF; Chen LC; Chen CH; Lin JK; Liang YC; Lin CH; Lin SY; Chen CF; Ho YS
J Cell Biochem; 2002; 87(2):147-59. PubMed ID: 12244568
[TBL] [Abstract][Full Text] [Related]
15. Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines.
Uehara S; Yuki Y; Uno Y; Inoue T; Sasaki E; Yamazaki H
Xenobiotica; 2018 Apr; 48(4):342-347. PubMed ID: 28436281
[TBL] [Abstract][Full Text] [Related]
16. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine.
Kishimoto W; Hiroi T; Sakai K; Funae Y; Igarashi T
Res Commun Mol Pathol Pharmacol; 1997 Dec; 98(3):273-92. PubMed ID: 9485522
[TBL] [Abstract][Full Text] [Related]
19. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.
Von Moltke LL; Greenblatt DJ; Granda BW; Duan SX; Grassi JM; Venkatakrishnan K; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1999 Jul; 48(1):89-97. PubMed ID: 10383565
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
Boxenbaum H
J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
